



Investor Relations:

Marty Tullio, Managing Partner
McCloud Communications, LLC
949.632.1900
marty@mccloudcommunications.com

New Study Says Just 5% of Mental Health Patients Receive Objective Test Before Getting Prescription Drugs

*96% of Patients Expect Doctor to Have Objective Information
CNS Response, Inc. releases DCA study*

Aliso Viejo, Calif., - December 19, 2013 - CNS Response, Inc. (OTCQB:CNSO) announced today that Decision Calculus Associates has released a new study today showing that just **5%** of patients treated for depression with medication receive an objective test prior to receiving a prescription. The study also showed that **96%** of patients expect their physician to do an objective physical test before prescribing psychotropic medications such as antidepressants.

"The dominant method of treatment today is trial & error, that's one of the reasons Psychiatric treatments fail more than they succeed," said George Carpenter, CEO of CNS Response. "Doctors use objective information about how your brain might respond to different medications because it's better medicine, and their patients are asking for it."

Overall, **80%** of patients felt their doctor used "trial and error" prescribing. This number went up to **91%** when three or more medications were tried before finding one that worked.

The results are from an anonymous online survey of 80 respondents fielded by Decision Calculus Associates. More in depth survey results, methodology and questionnaire are available at: <http://www.cnsresponse.com/topline-patients-want-more-information.html>

Consumers want objective information to guide the choice of treatment. This survey suggests Psychiatry has an opportunity to improve patient doctor relationships with more information.

CNS Response (CNS) is a clinical decision support company with a patented commercial neurometric platform, PEER Online, to predict drug response for treatment of brain disorders, including depression, anxiety, bipolar disorder and post-traumatic stress disorder. Using PEER Technology, CNS is currently performing a 2,000 subject trial at Walter Reed National Military Medical Center focusing on depression, post-traumatic stress disorder ("PTSD") and mild traumatic brain injury ("mTBI"). The trial currently has 51 sub-investigators and is active at Walter Reed National Military Medical Center and Fort Belvoir Community Hospital.

New Study Says Just 5% of Mental Health Patients Receive Objective Test Before Getting Prescription Drugs

Page 2

About CNS Response

CNS Response provides reference data and analytic tools for clinicians and researchers in psychiatry. Treatment for mental disorders has doubled in the last 20 years, and use of medications has grown over 400% -- but treatments fail more often than they succeed and over 17 million Americans have failed two or more medication therapies for their mental disorder. The company's Psychiatric EEG Evaluation Registry, or PEER Online, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the company's original physician-developed database, there are now more than 36,000 outcomes for 9,500 unique patients in the PEER registry. The objective of PEER Online is to avoid trial and error pharmacotherapy, the dominant approach for treatment resistant patients.

To discover more about the benefits of this patented technology for patients, physicians and payers, please visit www.cnsresponse.com. Medical professionals interested in learning more can contact CNS Response at PEERinfo@cnsresponse.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

###